Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143840
Corporate User License Price USD 6000
Corporate User License Price INR 431520
Site License Price USD 4000
Site License Price INR 287680
Request a Quote

Report Title

Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2016



Executive Summary

Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2016', provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS)

The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects

The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Severe Acute Respiratory Syndrome (SARS) Overview 8

Therapeutics Development 9

Pipeline Products for Severe Acute Respiratory Syndrome (SARS)-Overview 9

Pipeline Products for Severe Acute Respiratory Syndrome (SARS)-Comparative Analysis 10

Severe Acute Respiratory Syndrome (SARS)-Therapeutics under Development by Companies 11

Severe Acute Respiratory Syndrome (SARS)-Therapeutics under Investigation by Universities/Institutes 12

Severe Acute Respiratory Syndrome (SARS)-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Severe Acute Respiratory Syndrome (SARS)-Products under Development by Companies 15

Severe Acute Respiratory Syndrome (SARS)-Products under Investigation by Universities/Institutes 16

Severe Acute Respiratory Syndrome (SARS)-Companies Involved in Therapeutics Development 17

CEL-SCI Corporation 17

GeneCure LLC 18

Inovio Pharmaceuticals, Inc. 19

Nanotherapeutics, Inc. 20

Novavax, Inc. 21

Phelix Therapeutics, LLC 22

Planet Biotechnology Inc. 23

Protein Sciences Corporation 24

Severe Acute Respiratory Syndrome (SARS)-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Combination Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 32

Drug Profiles 34

CEL-1000-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

D-3252-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Drugs to Inhibit Cathepsin L for Infectious Diseases-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

FDX-000-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Gene Therapy for Severe Acute Respiratory Syndrome-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

INO-4500-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Middle East respiratory syndrome coronavirus vaccine-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ML-188-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibody for SARS Virus Infections-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

RBD-219N1-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

SARS (virus like particle) vaccine-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

severe acute respiratory syndrome vaccine-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

SSYA-10001-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Severe Acute Respiratory Syndrome (SARS)-Dormant Projects 50

Severe Acute Respiratory Syndrome (SARS)-Discontinued Products 53

Severe Acute Respiratory Syndrome (SARS)-Product Development Milestones 54

Featured News & Press Releases 54

Oct 19, 2015: Inovio and Partner Advance MERS Vaccine 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016 9

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS)-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Severe Acute Respiratory Syndrome (SARS)-Pipeline by CEL-SCI Corporation, H2 2016 17

Severe Acute Respiratory Syndrome (SARS)-Pipeline by GeneCure LLC, H2 2016 18

Severe Acute Respiratory Syndrome (SARS)-Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 19

Severe Acute Respiratory Syndrome (SARS)-Pipeline by Nanotherapeutics, Inc., H2 2016 20

Severe Acute Respiratory Syndrome (SARS)-Pipeline by Novavax, Inc., H2 2016 21

Severe Acute Respiratory Syndrome (SARS)-Pipeline by Phelix Therapeutics, LLC, H2 2016 22

Severe Acute Respiratory Syndrome (SARS)-Pipeline by Planet Biotechnology Inc., H2 2016 23

Severe Acute Respiratory Syndrome (SARS)-Pipeline by Protein Sciences Corporation, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Assessment by Combination Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Severe Acute Respiratory Syndrome (SARS)-Dormant Projects, H2 2016 50

Severe Acute Respiratory Syndrome (SARS)-Dormant Projects (Contd..1), H2 2016 51

Severe Acute Respiratory Syndrome (SARS)-Dormant Projects (Contd..2), H2 2016 52

Severe Acute Respiratory Syndrome (SARS)-Discontinued Products, H2 2016 53

List of Figures

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2016 9

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS)-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 27

Number of Products by Stage and Targets, H2 2016 27

Number of Products by Mechanism of Actions, H2 2016 29

Number of Products by Stage and Mechanism of Actions, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

CEL-SCI Corporation

GeneCure LLC

Inovio Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Planet Biotechnology Inc.

Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Therapeutic Products under Development, Key Players in Severe Acute Respiratory Syndrome (SARS) Therapeutics, Severe Acute Respiratory Syndrome (SARS) Pipeline Overview, Severe Acute Respiratory Syndrome (SARS) Pipeline, Severe Acute Respiratory Syndrome (SARS) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand